Ignite Creation Date:
2025-12-25 @ 3:47 AM
Ignite Modification Date:
2025-12-26 @ 2:34 AM
Study NCT ID:
NCT05633602
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-05-28
First Post:
2022-11-21
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
Sponsor:
SWOG Cancer Research Network
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-03-14
Start Date Type:
ACTUAL
Primary Completion Date:
2027-01-15
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-03-15
Completion Date Type:
ESTIMATED
First Submit Date:
2022-11-21
First Submit QC Date:
None
Study First Post Date:
2022-12-01
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-05-21
Last Update Post Date:
2025-05-28
Last Update Post Date Type:
ACTUAL